Medicine information CELSENTRI 25mg film-coated tablets

Product code:: W64979001
Quantity:: 120
Indicated for:: HIV-1 infection
Route of administration:: oral
Substance:: maraviroc (viral entry inhibitor)
ATC: J05AX09 — Antiinfectives for systemic use | Direct acting antivirals | Other antivirals

Maraviroc is a medication used in the treatment of HIV-1 infection. It acts as a CCR5 receptor antagonist, blocking the virus from entering host cells.

The medication is taken orally, usually in tablet form, and is used in combination with other antiretroviral drugs to enhance treatment efficacy. It is important to follow the treatment regimen prescribed by the doctor.

Side effects may include nausea, fatigue, dizziness, or upper respiratory tract infections. In rare cases, severe allergic reactions or liver problems may occur.

Maraviroc is not recommended for patients with severe liver impairment or those with CCR5 receptor mutations that render the treatment ineffective.

General data about CELSENTRI 25mg

Substance:: maraviroc
Date of latest medicines list:: 01-12-2018
Product code:: W64979001
Strength:: 25mg
Pharmaceutical form:: film-coated tablets
Quantity:: 120
Product type:: Original
Prescription status:: P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:: PFIZER MANUFACTURING DEUTSCHLAND GMBH - GERMANIA
Holder:: VIIV HEALTHCARE BV - OLANDA
Number:: 418/2007/11
Shelf life:: 5 years

Pharmaceutical forms available for maraviroc

Strengths available for maraviroc

150mg
20mg/ml
25mg
300mg
75mg

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

EMA product information (SmPC and leaflet)

Added to database:: 11/08/2009
Source record updated:: 12/01/2026

Warnings:

Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning

Use during pregnancy only on medical advice.